Capital One analyst Zegbeh Jallah initiated coverage of EyePoint with an Overweight rating and $44 price target. EyePoint, one of a few companies aiming to develop a treatment, EYP-1901, for retinal diseases that would allow patients to have meaningfully fewer eye injections than they currently do with Eylea and other approved anti-VEGF therapies, has the potential to “truly take market share from Eylea,” the analyst tells investors. The stock up 300%-plus in recent weeks, but the firm thinks the stock price “does not fully reflect the upside potential of EYP-1901” and the firm sees the December update from the Phase 2 Wet AMD study, DAVIO 2, offering “massive upside,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EYPT:
- Short Report: Eyepoint Pharmaceuticals bears cut bait after Phase 2 trial data
- Biotech Alert: Searches spiking for these stocks today
- EyePoint price target raised to $30 from $20 at Mizuho
- Insider Trading: EyePoint’s (NASDAQ:EYPT) Insider Makes an Enormous Purchase
- EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering